Skip to content

Onsite Tobacco Cessation Treatment for Patients With PAD

Onsite Tobacco Cessation Treatment for Patients With Peripheral Artery Disease (PAD): A Feasibility Study

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05469698
Acronym
PAD
Enrollment
15
Registered
2022-07-22
Start date
2022-08-16
Completion date
2024-07-31
Last updated
2024-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Artery Disease, Tobacco Cessation

Brief summary

Tobacco cessation treatment is needed for individuals with peripheral artery disease (PAD) to improve symptoms, lower cardiovascular risk, and prevent amputation. While such treatment is effective, many PAD patients do not receive cessation therapy. Participants will receive nicotine replacement therapy, counseling, and and complete questionnaires. We hypothesize that integrating tobacco cessation services into a dedicated PAD clinic (OU CVI Limb Preservation Clinic) can improve tobacco cessation rates and improve PAD-related health outcomes in this at risk population.

Interventions

BEHAVIORALTobacco Treatment Research Program Standard Care

Participants interested in quitting tobacco will be offered standard tobacco cessation care including nicotine replacement therapy and counseling.

Sponsors

University of Oklahoma
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Have diagnosed peripheral artery disease * Tobacco user * 18 years of age or older * Willing/able to attend all study visits * Be able to read, speak, and understand English

Exclusion criteria

* Do not meet the specified inclusion criteria above

Design outcomes

Primary

MeasureTime frameDescription
Biochemically confirmed abstinence13 weeks post enrollmentWe will measure the biochemically-confirmed self-reported smoking cessation rate at 13 weeks post-enrollment (a cessation rate of ≥ 15-20% will be a sign of feasibility).

Secondary

MeasureTime frameDescription
Rate of enrollmentDuration of the study (approximately 6 months)We will measure the rate of enrollment over those approached to be in the study (≥ 25% enrolled will indicate feasibility).

Other

MeasureTime frameDescription
Improvements in PADBaseline to 13 weeks post enrollmentWe will evaluate improvements among participants based on their responses in surveys.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026